Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideABTAbbott Laboratories
FinDog View：Neutral
| Metric | ABT | AMGN |
|---|
| Close | 102.36 | 376.35 |
| Market Cap | $177B | $203B |
| 1M | −7.26% | −10.26% |
| P/E (TTM) | 33.2 | 23.3 |
| Forward P/E | 18.1 | 16.9 |
| P/E 5-Yr Percentile | 66 | 27 |
| P/S | 3.9 | 5.4 |
| P/B | 3.5 | 17.4 |
| Dividend Yield | 1.98% | 3.21% |
| Latest Quarter Revenue | $11.2B | $10.1B |
| Revenue YoY | +7.8% | +9.5% |
| Gross Margin | 56.2% | 72.0% |
| Latest Quarter EPS | 0.61 | 4.37 |
| Avg Post-Earnings Move | ±1.6% | ±5.2% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.81% | 2.60% |
| 90-Day Net Insider Buying | −$46.7M | −$4.1M |
ABT · Revenue, Last 8 Quarters ($B)
AMGN · Revenue, Last 8 Quarters ($B)
